| P50 | author | Lionel Apetoh | Q40455935 |
| P2093 | author name string | Thaiz Rivera Vargas | |
| P2860 | cites work | Immunogenicity signals 1,2,3 ... and 0. | Q55059065 |
| | Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape | Q57272360 |
| | Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope | Q58895662 |
| | Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases | Q59084980 |
| | A Mouse Model of Zika Virus Pathogenesis | Q24261408 |
| | A Toll-like receptor recognizes bacterial DNA | Q24290668 |
| | HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 | Q24306365 |
| | Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway | Q24306635 |
| | STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling | Q24336398 |
| | The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway | Q24538824 |
| | A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death | Q24620548 |
| | Vaccine adjuvants as potential cancer immunotherapeutics | Q26752522 |
| | STING: infection, inflammation and cancer | Q26776009 |
| | Regulation of HMGB1 release by inflammasomes | Q26829877 |
| | Towards the introduction of the 'Immunoscore' in the classification of malignant tumours | Q27026489 |
| | Dendritic cells and the control of immunity | Q27860918 |
| | Damage-associated molecular patterns in cancer: a double-edged sword | Q28067434 |
| | Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA | Q28118718 |
| | Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 |
| | Release of chromatin protein HMGB1 by necrotic cells triggers inflammation | Q28131815 |
| | Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases | Q28138370 |
| | HMG-1 as a late mediator of endotoxin lethality in mice | Q28139166 |
| | Activation of interferon regulatory factor 3 in response to DNA-damaging agents | Q28145891 |
| | Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose | Q28155894 |
| | Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo | Q28216180 |
| | HMGB1 loves company | Q28243671 |
| | Type I interferon is selectively required by dendritic cells for immune rejection of tumors | Q28248500 |
| | Type I interferons in infectious disease | Q28255842 |
| | HMG proteins: dynamic players in gene regulation and differentiation | Q28267498 |
| | Immune response against dying tumor cells | Q28271233 |
| | Approaching the asymptote? Evolution and revolution in immunology | Q28274344 |
| | Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 |
| | Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP | Q28287589 |
| | Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91 | Q28481417 |
| | Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium | Q28508897 |
| | STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity | Q28509328 |
| | Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells | Q28533749 |
| | The role of tumor stroma in the interaction between tumor and immune system | Q36070711 |
| | CD47 blockade triggers T cell-mediated destruction of immunogenic tumors | Q36137576 |
| | cGMP-AMP synthase paves the way to autoimmunity | Q36207307 |
| | Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases | Q36207338 |
| | Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin, and ERp57. | Q36242107 |
| | Current and potential uses of imiquimod | Q36283259 |
| | Cell to cell communication in response to mechanical stress via bilateral release of ATP and UTP in polarized epithelia | Q36293783 |
| | Topoisomerase II Inhibitors Induce DNA Damage-Dependent Interferon Responses Circumventing Ebola Virus Immune Evasion | Q36335123 |
| | STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas | Q36393153 |
| | Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death | Q36403093 |
| | Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response | Q36453386 |
| | Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice | Q36497106 |
| | Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis | Q36586185 |
| | Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases | Q36597510 |
| | DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking | Q36637260 |
| | The anticancer immune response: indispensable for therapeutic success? | Q36677608 |
| | Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer | Q36777278 |
| | Development of TLR9 agonists for cancer therapy | Q36809776 |
| | The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer | Q36862687 |
| | An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer | Q36985056 |
| | The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy | Q36990578 |
| | Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity | Q36990647 |
| | Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE | Q37019629 |
| | The origin and properties of extracellular DNA: from PAMP to DAMP. | Q37047827 |
| | Toll-like receptor 9 (TLR9) agonists in the treatment of cancer | Q37050998 |
| | Immunogenicity of anthracyclines: moving towards more personalized medicine | Q37114351 |
| | Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death | Q37133168 |
| | RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. | Q37152947 |
| | Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer | Q37252611 |
| | Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer | Q37278036 |
| | Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer | Q37323046 |
| | The immunogenicity of tumor cell death | Q37362989 |
| | Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer | Q37532636 |
| | RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages | Q28568915 |
| | An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy | Q28729093 |
| | Topoisomerase levels determine chemotherapy responsein vitroandin vivo | Q29395563 |
| | Tolerance, danger, and the extended family | Q29547532 |
| | DAMPs, PAMPs and alarmins: all we need to know about danger | Q29547535 |
| | Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte | Q29615441 |
| | How dying cells alert the immune system to danger | Q29615501 |
| | Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice | Q29615615 |
| | Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors | Q29615665 |
| | Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 |
| | Self-eating and self-killing: crosstalk between autophagy and apoptosis | Q29617748 |
| | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 |
| | Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 |
| | Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 |
| | Molecular identification of a danger signal that alerts the immune system to dying cells | Q29619497 |
| | Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 |
| | Immunogenic cell death in cancer therapy | Q29620118 |
| | Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE | Q29620722 |
| | Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance | Q30436506 |
| | Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses | Q31838449 |
| | Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion | Q33193752 |
| | Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1 | Q33602916 |
| | CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival | Q33615807 |
| | Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. | Q33718199 |
| | Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients | Q33743256 |
| | Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review | Q33751106 |
| | Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection | Q33887844 |
| | A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib | Q33976734 |
| | Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 |
| | Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface | Q34011327 |
| | Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity | Q34024427 |
| | About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 |
| | Extracellular metabolism of ATP and other nucleotides | Q34101805 |
| | Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. | Q34140085 |
| | DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown | Q34160434 |
| | Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen | Q34211237 |
| | The ins and outs of calreticulin: from the ER lumen to the extracellular space. | Q34221174 |
| | Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus | Q34224780 |
| | Immunogenic cell death and DAMPs in cancer therapy | Q34311701 |
| | Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. | Q34324135 |
| | DNA damage-induced activation of ATM and ATM-dependent signaling pathways | Q34336538 |
| | Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. | Q34374085 |
| | Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs | Q34514089 |
| | Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. | Q34539873 |
| | P2 receptors: new potential players in atherosclerosis | Q34542194 |
| | Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 |
| | Toll-like receptors in systemic autoimmune disease | Q34576448 |
| | Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox | Q34685501 |
| | Programming CD8+ T cells for effective immunotherapy. | Q34976602 |
| | Roles of toll-like receptors in natural interferon-producing cells as sensors in immune surveillance | Q35024774 |
| | Recognition of pathogen-associated molecular patterns by TLR family | Q35044748 |
| | Extracellular ATP as a signaling molecule for epithelial cells | Q35209159 |
| | Predicting the functional impact of protein mutations: application to cancer genomics | Q35224321 |
| | STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. | Q35263440 |
| | Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 |
| | Immunotherapeutic uses of CpG oligodeoxynucleotides | Q35730784 |
| | Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells | Q35740077 |
| | Consensus nomenclature for CD8(+) T cell phenotypes in cancer | Q35798822 |
| | STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade | Q35858368 |
| | TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity | Q35908369 |
| | HMGB1 is a therapeutic target for sterile inflammation and infection | Q35953553 |
| | Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity | Q36007039 |
| | Leukocyte P2 receptors: a novel target for anti-inflammatory and anti-tumor therapy | Q36048104 |
| | Pathology of lupus nephritis | Q36054832 |
| | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | Q42182888 |
| | Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 |
| | An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma | Q42644358 |
| | Vaccine therapy for pancreatic cancer | Q42660104 |
| | STUDIES ON THE SENSITIZATION OF ANIMALS WITH SIMPLE CHEMICAL COMPOUNDS : III. ANAPHYLAXIS INDUCED BY ARSPHENAMINE. | Q42799420 |
| | Features of systemic lupus erythematosus in Dnase1-deficient mice | Q42801296 |
| | Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors | Q43546471 |
| | The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells | Q43628934 |
| | Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. | Q43893076 |
| | Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. | Q44122413 |
| | Histopathology of lupus-like nephritis in Dnase1-deficient mice in comparison to NZB/W F1 mice | Q44130518 |
| | Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes | Q44208206 |
| | P2X7 receptor inhibition improves recovery after spinal cord injury | Q44982503 |
| | A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. | Q46094829 |
| | Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 | Q46389190 |
| | A critical function for type I interferons in cancer immunoediting | Q46542397 |
| | T cell immunity induced by live, necrotic, and apoptotic tumor cells | Q47231797 |
| | Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response | Q48030659 |
| | DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity | Q48370424 |
| | ATP-induced Ca2+ response mediated by P2U and P2Y purinoceptors in human macrophages: signalling from dying cells to macrophages. | Q50515209 |
| | DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. | Q51752532 |
| | Noradrenaline and ATP as cotransmitters in sympathetic nerves. | Q52242598 |
| | Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. | Q52907227 |
| | The ATM-mediated DNA-damage response: taking shape. | Q53618038 |
| | Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. | Q54149882 |
| | Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. | Q54196124 |
| | Metabolic DNA as the origin of spontaneously released DNA? | Q54797396 |
| | TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells | Q37729984 |
| | The virtosome-a novel cytosolic informative entity and intercellular messenger | Q37799777 |
| | Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation | Q37844960 |
| | Immune parameters affecting the efficacy of chemotherapeutic regimens | Q37848665 |
| | Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity | Q37925064 |
| | The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. | Q38010746 |
| | Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination | Q38021271 |
| | CpG plus radiotherapy: a review of preclinical works leading to clinical trial | Q38036658 |
| | Immune sensing of DNA | Q38109307 |
| | Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer | Q38115968 |
| | The interferon response to intracellular DNA: why so many receptors? | Q38130353 |
| | Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species | Q38335343 |
| | Perception of self: distinguishing autoimmunity from autoinflammation | Q38474054 |
| | The emerging roles of the STING adaptor protein in immunity and diseases | Q38661586 |
| | Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. | Q38823705 |
| | Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity | Q38874781 |
| | DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity | Q38908391 |
| | Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing | Q38959510 |
| | The key role of calreticulin in immunomodulation induced by chemotherapeutic agents | Q38980305 |
| | Immunogenic cell death in cancer and infectious disease | Q38982422 |
| | The P2X7 Receptor-Interleukin-1 Liaison. | Q39209974 |
| | An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance | Q39308911 |
| | Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin | Q39423568 |
| | Extracellular ATP: effects, sources and fate | Q39500098 |
| | Human tumor cells killed by anthracyclines induce a tumor-specific immune response | Q39538516 |
| | Immunogenic death of colon cancer cells treated with oxaliplatin | Q39780621 |
| | Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection | Q39898411 |
| | Association of the autoimmune disease scleroderma with an immunologic response to cancer | Q40043509 |
| | Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer | Q40434251 |
| | Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells | Q40686939 |
| | Purinergic mechanism in the immune system: A signal of danger for dendritic cells. | Q40722726 |
| | Endotoxin activation of macrophages does not induce ATP release and autocrine stimulation of P2 nucleotide receptors | Q40836862 |
| | Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 |
| | Viruses transfer the antiviral second messenger cGAMP between cells | Q41079643 |
| | Transmission of innate immune signaling by packaging of cGAMP in viral particles | Q41079648 |
| | Calreticulin | Q41351885 |
| | The genetic defect in ataxia-telangiectasia | Q41464274 |
| | Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells | Q41701341 |
| | Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death | Q42115292 |
| P433 | issue | 1 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 175-193 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | Immunological Reviews | Q15724582 |
| P1476 | title | Danger signals: Chemotherapy enhancers? | |
| P478 | volume | 280 | |